Head-to-head evidence
CYB003 vs Mebufotenin (5-MeO-DMT)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
CYB003
Developed by Cybin
NCT05385783 · Phase 1/2 · completed
The study randomized 57 participants and used quadruple masking, with placebo comparator sessions in both the major depressive disorder and healthy-participant groups. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary outcomes are safety measures; the MADRS result is the sponsor-designated primary efficacy endpoint from topline press releases, not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT06793397 (registry estimate)
Mebufotenin (5-MeO-DMT) · GH001
Developed by GH Research
NCT05800860 · Phase 2 · completed
The study randomly assigned 81 participants and used quadruple blinding with a placebo comparator. Its primary endpoint was the change in MADRS depression scores from baseline to Day 7. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CYB003's landscape · Mebufotenin (5-MeO-DMT)'s landscape